Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Parsifal Capital Management LP

Key Points

• Parsifal Capital Management LP reduced its stake in Teva Pharmaceutical Industries by 3.9%, selling 169,814 shares, and now holds approximately $64.6 million worth of the stock.
• Several hedge funds have significantly increased their holdings in Teva, with Harel Insurance Investments boosting its stake by over 197,885%, now holding more than 22 million shares.
• Teva recently reported earnings that exceeded analysts' expectations, posting $0.66 EPS while setting guidance for fiscal year 2025 at 2.500-2.600 EPS.

Parsifal Capital Management LP decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 3.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,202,187 shares of the company's stock after selling 169,814 shares during the quarter. Teva Pharmaceutical Industries accounts for about 5.6% of Parsifal Capital Management LP's investment portfolio, making the stock its 5th largest holding. Parsifal Capital Management LP owned approximately 0.37% of Teva Pharmaceutical Industries worth $64,588,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Golden State Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $39,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $43,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $54,000. Banque Cantonale Vaudoise acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $74,000. Finally, Brooklyn Investment Group grew its stake in shares of Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock valued at $77,000 after acquiring an additional 4,014 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded up $0.39 on Tuesday, hitting $19.69. The stock had a trading volume of 12,962,752 shares, compared to its average volume of 9,877,037. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The stock has a market cap of $22.58 billion, a price-to-earnings ratio of -123.06, a P/E/G ratio of 1.12 and a beta of 0.72. The company's 50-day moving average is $17.15 and its two-hundred day moving average is $16.43.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company's quarterly revenue was up .3% compared to the same quarter last year. During the same period last year, the company earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TEVA. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Finally, The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.